TCI Wealth Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

TCI Wealth Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-204	Closed	-$11K	–	2347
2023 Q1	$11K	Hold	204	–	–	﹤0.01%	1025
2022 Q4	$10.8K	Buy	204 +57	+39%	+$2.86K	﹤0.01%	1026
2022 Q3	$7K	Sell	147 -24	-14%	-$1.25K	﹤0.01%	1302
2022 Q2	$10K	Buy	171 +24	+16%	+$1.36K	﹤0.01%	1043
2022 Q1	$9K	Buy	147 +29	+25%	+$1.51K	﹤0.01%	1209
2021 Q4	$6K	Hold	118	–	–	﹤0.01%	1592
2021 Q3	$4K	Sell	118 -22	-16%	-$765	﹤0.01%	1850
2021 Q2	$6K	Buy	140 +42	+43%	+$1.55K	﹤0.01%	1379
2021 Q1	$3K	Buy	+98	New	+$3.4K	﹤0.01%	1616

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCI Wealth Advisors's ITCI Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2023, closing a stake of 204 shares — an estimated $11K sold.

TCI Wealth Advisors first reported a position in ITCI in Q1 2021 and held it in 9 quarters. The position peaked at $11K in Q1 2023. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

TCI Wealth Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 204 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $11K.
TCI Wealth Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2021 and held it in 9 quarters.
TCI Wealth Advisors's Intra-Cellular Therapies Inc. position peaked at $11K in Q1 2023.
288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.